Ascendis Pharma Launches 2nd TransCon™ Product: YORVIPATH® Now Available in Germany and Austria for Adults with Chronic Hypoparathyroidism

Source: Nasdaq GlobeNewswire / 31 Jan 2024 16:01:00   America/New_York